Dehui Zou

3.1k total citations
162 papers, 1.4k citations indexed

About

Dehui Zou is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Dehui Zou has authored 162 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 72 papers in Hematology and 67 papers in Pathology and Forensic Medicine. Recurrent topics in Dehui Zou's work include Lymphoma Diagnosis and Treatment (64 papers), Chronic Lymphocytic Leukemia Research (52 papers) and Multiple Myeloma Research and Treatments (52 papers). Dehui Zou is often cited by papers focused on Lymphoma Diagnosis and Treatment (64 papers), Chronic Lymphocytic Leukemia Research (52 papers) and Multiple Myeloma Research and Treatments (52 papers). Dehui Zou collaborates with scholars based in China, United States and United Kingdom. Dehui Zou's co-authors include Lugui Qiu, Yan Xu, Gang An, Shuhui Deng, Weiwei Sui, Shuhua Yi, Mu Hao, Zengjun Li, Junyuan Qi and Haiyan Yang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Dehui Zou

138 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dehui Zou China	20	666	554	519	417	364	162	1.4k
Kamel Laribi France	17	606 0.9×	604 1.1×	336 0.6×	329 0.8×	321 0.9×	62	1.2k
Miguel Alcoceba Spain	21	442 0.7×	362 0.7×	322 0.6×	439 1.1×	460 1.3×	79	1.3k
Thomas Melchardt Austria	23	559 0.8×	247 0.4×	380 0.7×	396 0.9×	486 1.3×	93	1.4k
Parameswaran Venugopal United States	21	412 0.6×	1.1k 1.9×	684 1.3×	339 0.8×	482 1.3×	130	1.9k
Batia Avni Israel	19	449 0.7×	399 0.7×	419 0.8×	243 0.6×	300 0.8×	66	1.4k
J. Rifón Spain	18	316 0.5×	515 0.9×	641 1.2×	253 0.6×	361 1.0×	60	1.5k
Seongseok Yun United States	18	464 0.7×	344 0.6×	306 0.6×	206 0.5×	248 0.7×	79	1.1k
Thomas Moehler Germany	25	739 1.1×	1.4k 2.5×	1.1k 2.0×	158 0.4×	281 0.8×	69	2.1k
Álvaro Aguayo Mexico	19	506 0.8×	867 1.6×	933 1.8×	202 0.5×	501 1.4×	46	1.8k
Anastasia Pouli Greece	21	880 1.3×	1.2k 2.1×	850 1.6×	239 0.6×	343 0.9×	54	1.8k

Countries citing papers authored by Dehui Zou

Since Specialization

Citations

This map shows the geographic impact of Dehui Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dehui Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dehui Zou more than expected).

Fields of papers citing papers by Dehui Zou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dehui Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dehui Zou. The network helps show where Dehui Zou may publish in the future.

Co-authorship network of co-authors of Dehui Zou

This figure shows the co-authorship network connecting the top 25 collaborators of Dehui Zou. A scholar is included among the top collaborators of Dehui Zou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dehui Zou. Dehui Zou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yan, Yuting, Tingyu Wang, Tengteng Yu, et al.. (2025). Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study. Clinical Cancer Research. 31(10). 1856–1864. 1 indexed citations

Wang, Yi, Yuting Yan, Dandan Shan, et al.. (2025). Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma. Cancer Biology and Medicine. 22(2). 177–189. 1 indexed citations

Liu, Wei, Xiaojuan Wang, Chunyang Wang, et al.. (2024). Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Journal for ImmunoTherapy of Cancer. 12(3). e008450–e008450. 9 indexed citations

Li, Chunrui, Dehui Zou, He Huang, et al.. (2024). Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study. Blood. 144(Supplement 1). 4761–4761. 2 indexed citations

Xiong, Yu, Tengteng Yu, Shuaishuai Zhang, et al.. (2024). Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report. Journal for ImmunoTherapy of Cancer. 12(11). e010080–e010080. 2 indexed citations

Sui, Weiwei, Tengteng Yu, Yuting Yan, et al.. (2024). CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities. Blood. 144(Supplement 1). 3386–3386.

Liu, Jiahui, Yan Xu, Weiwei Sui, et al.. (2024). Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. American Journal of Hematology. 99(4). 523–533. 7 indexed citations

Xu, Yan, Wensi Li, Gang An, et al.. (2023). Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy. Blood. 142(Supplement 1). 6864–6864. 1 indexed citations

Liu, Nan, Ding Tang, Kai Zhang, et al.. (2023). 743MO Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter phase II study. Annals of Oncology. 34. S509–S509. 1 indexed citations

10.

Li, Lingna, Yuting Yan, Yan Xu, et al.. (2023). Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. Cancer Research Communications. 3(9). 1770–1780. 4 indexed citations

11.

Ying, Zhitao, Haiyan Yang, Ye Guo, et al.. (2023). Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. Cytotherapy. 25(5). 521–529. 13 indexed citations

12.

Song, Yuqin, Zhitao Ying, Haiyan Yang, et al.. (2021). Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China. Blood. 138(Supplement 1). 3557–3557. 2 indexed citations

13.

Yu, Tengteng, Xiaoke Ma, Weiwei Sui, et al.. (2020). Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Molecular Cancer Research. 18(7). 1063–1073. 21 indexed citations

14.

Song, Yuqin, Keshu Zhou, Dehui Zou, et al.. (2020). Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research. 26(16). 4216–4224. 111 indexed citations

15.

Ding, Xiao, Wenyang Huang, Yi Peng, et al.. (2020). Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. Annals of Hematology. 99(6). 1331–1339. 8 indexed citations

16.

Li, Heng, Shuhua Yi, Wenjie Xiong, et al.. (2017). Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.. SHILAP Revista de lepidopterología. 130(2). 135–142. 5 indexed citations

17.

Deng, Shuhui, Yan Xu, Gang An, et al.. (2015). [Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China].. PubMed. 36(6). 501–6. 1 indexed citations

18.

Feng, Xiaoyan, Shuhui Deng, Gang An, et al.. (2015). [Clinical characteristics and survival of newly diagnosed multiple myeloma patients under 40 years old from single center and literature review].. PubMed. 36(11). 933–6. 1 indexed citations

19.

Li, Fei, Mu Hao, Xiaoyan Feng, et al.. (2015). Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leukemia Research. 39(7). 793–799. 22 indexed citations

20.

Yi, Shuhua, Rui Cui, Zengjun Li, et al.. (2014). Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. Chinese Medical Journal. 127(12). 2327–2331. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact